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Ocular candidiasis is a major complication of Candida 35 
bloodstream infection (BSI).  This study was performed to reveal 36 
clinical characteristics of ocular candidiasis.  Of the 220 patients 37 
with Candida BSI, 204 cases received ophthalmology 38 
consultations between January 2005 and December 2011 at two 39 
teaching hospitals.  Fifty-four (26.5%) cases had findings 40 
consistent with the diagnosis of ocular candidiasis.  Of these 54 41 
cases, 43 (79.6%) were diagnosed within 7 days after a positive 42 
blood culture.  Among ocular candidiasis cases, more cases were 43 
due to Candida albicans (P = 0.034 OR; 3.68 95% CI 1.11-12.2) 44 
and had higher beta-D-glucan values (P = 0.001 OR; 9.99 95% CI 45 
2.60 - 21.3).  We need to consider fundoscopic examination to be 46 
performed within first 7 days of therapy, especially for those 47 
patients who have C. albicans BSIs and higher beta-D-glucan 48 
values.  Additionally, follow-up fundoscopic examination should 49 




Bloodstream infections (BSIs) caused by Candida species have 52 
been reported to be increasingly frequent in recent decades, 53 
possibly due to rapid changes in medical practice.  Candida 54 
BSI can lead to hematogenous dissemination and metastatic 55 
ocular infection with potentially devastating consequences.  56 
Consequently, a rise in related mortality and prolonged 57 
hospitalisation has been reported [Edmond et al., 1999; Jarvis et 58 
al., 1995; Kao et al., 1999; Pfaller and Diekema, 2007; Rentz et al., 59 
1998; Sheng et al., 2005; Wisplinghoff et al., 2004].   60 
Normally, patients who have chorioretinitis alone are often 61 
asymptomatic and respond better to systemic antifungal therapy 62 
than those with vitreal involvement.  However, in advanced 63 
stages, the intravitreal injection of an antifungal agent with or 64 
without vitrectomy is needed.  Thus, it is very important for 65 
doctors to properly diagnose ocular candidiasis in the early stages 66 
of the infection.   67 
In this study, patients with blood cultures positive for 68 
Candida BSIs were reviewed for the incidence and clinical 69 
characteristics of ocular candidiasis to reveal the risk factors of 70 
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ocular candidiasis. 71 
 72 
Materials and Methods 73 
Study design 74 
This study was performed at two teaching hospitals in Kyoto, 75 
Japan.  Kyoto University Hospital (KUH) is a tertiary care 76 
university hospital with 1240 beds, and Katsura Hospital is an 77 
emergency hospital with 585 beds.  Infectious disease physicians 78 
perform proactive interventions for all patients with BSI in these 79 
hospitals.  In cases of Candida BSIs, catheter removal is 80 
recommended, blood cultures are collected to confirm all negative 81 
results, and finally, fundoscopy is performed by ophthalmologists 82 
usually within first 7 days of therapy.  Candida BSI was defined 83 
by at least one positive blood culture for Candida species and a 84 
clinical sign of infection (e.g., fever, hypotension or tachypnea).     85 
Two hundred and twenty cases of Candida BSIs were 86 
diagnosed in the two Kyoto teaching hospitals from January 2005 87 
to December 2011.  To assess the incidence and clinical 88 
characteristics of patients with ocular involvement, we performed 89 
medical chart reviews of the Candida BSI patients who had 90 
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consulted ophthalmologists.  For the classification of ocular 91 
candidiasis, we incorporated the criteria proposed by Oude Lashof 92 
[Oude Lashof et al., 2011].  Proven ocular candidiasis was 93 
defined as ocular lesions in combination with positive histology or 94 
a positive culture of a vitreous aspirate.  Probable Candida 95 
endophthalmitis was defined as vitritis or fluffy lesions with 96 
extensions into the vitreous humour.  Probable Candida 97 
chorioretinitis was defined as deep focal white infiltrates in the 98 
retina.  If signs of chorioretinitis were observed in patients with 99 
an underlying systemic disease that reportedly exhibits similar 100 
lesions (e.g., diabetes, hypertension or concomitant bacteremia), 101 
these cases were classified as possible ocular candidiasis.  102 
Clinical information acquired from medical charts included age, 103 
sex, underlying diseases, receipt of corticosteroids or other 104 
immunosuppressive agents during the previous 30 days, any 105 
antimicrobial therapy during the previous 30 days, surgery 106 
during the previous 30 days, time to first negative blood culture, 107 
interval between blood culture and antifungal therapy, interval 108 
between sign of infection and removal of the catheter or 109 
antifungal agents, interval between positive fungal culture and 110 
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catheter removal, the specific fungal species, antifungal therapy 111 
and 30-day mortality.  Digestive tract involvement included any 112 
gastrointestinal disorders such as malignancies of digestive tract 113 
and inflammatory bowel diseases.  The (1,3)-β-D-glucan (BDG) 114 
test values that were taken within 3 days after positive blood 115 
cultures were also evaluated.  At Katsura, the BDG values were 116 
determined using the Fungitec G test (Seikagaku Corporation, 117 
Tokyo, Japan).  At KUH, the BDG values were determined using 118 
the WAKO β-glucan test (Wako Pure Chemical Industries, Tokyo, 119 
Japan).  The results were analysed according to the 120 
manufacturer’s instructions.   121 
Statistical analysis 122 
Categorical variables were compared using Fisher’s exact test. 123 
Continuous variables were compared using the Kruskal-Wallis 124 
test or the Mann-Whitney U test.  BDG values under the limit of 125 
detection were considered to be 0.0 pg/mL.  Receiver-operating 126 
characteristic (ROC) curves for the BDG levels were constructed, 127 
and their optimal cut-off values were determined with the 128 
maximum Youden index.  Potential factors associated with 129 
ocular candidiasis were examined by Cox proportional hazards 130 
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regression analysis.  All covariates with a p-value of less than 131 
0.10 on univariate analyses were subjected to further selection by 132 
the above-mentioned multivariate analyses.  The data were 133 
analysed with PASW software version 18.0 (SPSS) for Microsoft 134 
Windows.  All P value tests were two-tailed, and P < 0.05 was 135 




Of the 220 patients with Candida BSI, 204 presented to 140 
ophthalmologists for the diagnosis of ocular candidiasis were 141 
included in this study.  Six of the 16 Candida BSI patients who 142 
did not consult ophthalmologists included critically ill patients 143 
whose prognosis had been presumed to be very poor or who died 144 
before the identification of positive fungal cultures.  145 
  Fifty-four (26.5%) of the 204 Candida BSI patients who were 146 
evaluated by ophthalmologists had fundoscopic abnormalities 147 
that met the criteria for ocular candidiasis.  Among ocular 148 
candidiasis cases, 10 were probable endophthalmitis, 24 were 149 




Epidemiologic characteristics 152 
The baseline characteristics of the study population are shown in 153 
Table 1.  The groups with or without ocular involvement did not 154 
differ with respect to age, sex, diabetes mellitus status, the use of 155 
immunosuppressive agents or the use of systemic antibiotics 156 
within the previous month, but more patients with ocular 157 
involvement had malignancies.  In addition, more patients with 158 
ocular manifestations had digestive tract abnormalities (e.g., 159 
digestive tract surgery, inflammatory bowel syndromes, 160 
malignancy of a digestive tract), whereas ocular candidiasis was 161 
rare in the departments of Dermatology, Rheumatology and 162 
Cardiovascular Surgery.  Ocular candidiasis patients were 163 
infected significantly more frequently with Candida albicans and 164 
less often with C. parapsilosis than patients without retinal 165 
lesions.  The length of time to the first negative blood culture, 166 
the time to catheter removal and the administration of antifungal 167 
agents did not differ between groups. 168 
Timing of fundscopic examination 169 
One hundred and eighty (88.2%) patients received fundscopic 170 
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examination once and 24 patients received twice or more.  171 
Ocular abnormalities consistent with ocular candidiasis were 172 
diagnosed within 7 days after positive blood culture in 43 patients, 173 
whereas 11 patients were diagnosed as having ocular candidiasis 174 
more than 8 days later (Figure 1).  Twenty-one (38.9%) patients 175 
were diagnosed within 3 days, and the average time from a 176 
positive blood culture to the diagnosis of ocular candidiasis was 177 
5.5 days.  The time to the first negative fungal culture was 178 
longer in the patients who were diagnosed with ocular candidiasis 179 
at the time of a second fundoscopy performed more than 8 days 180 
later after the positive fungal culture; all patients had 181 
malignancies, had diabetes mellitus or were being treated with 182 
immunosuppressive agents.   183 
BDG values and ocular candidiasis 184 
The diagnostic kit used for the measurement of BDG values 185 
differed between KUH and Katsura; therefore, we created ROC 186 
curves and determined that the appropriate cut-off values were 187 
22.5 and 42.7 for KUH and Katsura, respectively.  A case was 188 
defined as BDG-high if the BDG value was higher than the cut-off 189 
value.  Using the cut-off value, more patients with ocular 190 
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candidiasis than patients with non-ocular candidiasis were 191 
grouped as BDG-high cases.  There was no relationship between 192 
the BDG value and causative agents (data not shown).   193 
Clinical outcome 194 
Among 54 cases of ocular candidiasis, 42 patients completed 195 
antifungal therapy without any worsening of visual acuity, and 12 196 
patients died before the completion of antifungal therapy.  197 
Among the chorioretinitis cases, 33 out of 35 patients who 198 
provided a report indicated they had no ocular abnormalities.  199 
Among the ocular candidiasis cases, micafungin was prescribed to 200 
23 patients, and fluconazole was prescribed to 25 patients.  In 16 201 
of the 23 patients who received micafungin therapy, the 202 
antifungal treatment regimen was shifted to fluconazole or 203 
amphotericin-B after the diagnosis of ocular candidiasis. 204 
The 30-day mortality rate of patients with ocular abnormalities 205 
was also higher, although these differences were not statistically 206 
significant.   207 
Analysis of risk factors 208 
Candida albicans as the etiological agent (P = 0.034 OR; 3.68 95% 209 
CI 1.11-12.2) and higher beta-D-glucan values (P = 0.001 OR; 9.99 210 
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95% CI 2.60 – 21.3) were statistically significant for the risk 211 
factors of ocular candidiasis, as determined by multivariate 212 
regression analysis (Table 2).  213 
 214 
Discussion 215 
This study investigated the incidence and clinical characteristics 216 
of ocular candidiasis.  According to previous studies, the 217 
prevalence of ocular candidiasis is estimated to be between 1 - 218 
45% [Rodrguez-Adria´n et al., 2003; Oude Lashof et al., 2011, 219 
Parke et al., 1982; Brooks, 1989; Shah et al., 2008].  In this study, 220 
ocular abnormalities occurred in 26% of 204 patients.  It is likely 221 
that patient selection led to the comparatively high prevalence of 222 
ocular candidiasis.  Among our patients, 50% had malignancies, 223 
and more than 80% had predisposing risk factors such as 224 
antibiotic exposure, diabetes mellitus or the use of 225 
immunosuppressive therapy.  Furthermore, many patients had 226 
been admitted for gastrointestinal diseases.  Malignancy and 227 
gastrointestinal disease were statistically significant risk factors 228 
for ocular candidiasis as determined by chi-squared tests, 229 
although the statistical significance was not retained in the 230 
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multivariate regression model.  Considering the pathogenesis of 231 
endogenous ocular candidiasis, physical mucosal damage and 232 
changes in normal flora induced by broad-spectrum antibiotics or 233 
chemotherapy may facilitate the occurrence of ocular involvement.  234 
Thus, the high prevalence of ocular candidiasis observed in this 235 
study may have been the result of the severely 236 
immunocompromised state of many patients.   237 
Of all of the Candida species, C. albicans was observed to 238 
have the greatest propensity to cause ocular candidiasis.  In 239 
contrast, C. parapsilosis was associated with ocular 240 
manifestations significantly less frequently.  In this study, 241 
patients with ocular candidiasis were mostly infected with C. 242 
albicans, a finding that is consistent with prior reports (Donahue 243 
et al., 1994; Rodrguez-Adria´n et al., 2003; Oude Lashof et al., 244 
2011, Parke et al., 1982; Brooks, 1989; Shah et al., 2008).  Some 245 
of these cases occurred despite prompt catheter removal and the 246 
immediate administration of antifungal agents after the onset of 247 
Candida BSIs.  These results suggest that fungal virulence as 248 
well as host and treatment factors may be involved in the 249 
pathogenesis of ocular candidiasis.  It is likely that the high 250 
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prevalence of C. albicans may also have increased the rate of 251 
ocular candidiasis in this study.  252 
Several studies revealed that the prospective evaluation of 253 
circulating BDG in high-risk patients generates positive results 254 
that are available before the culture results and can improve the 255 
diagnosis of invasive candidiasis (Koo et al., 2009; Acosta et al., 256 
2011; Ostrosky-Zeichner et al., 2005).  In this study, more 257 
patients with ocular candidiasis had higher BDG values, and 258 
BDG positivity had a significant relationship with the 259 
development of ocular candidiasis.  However, there was no 260 
relationship between elevated BDG values and etiologic agents 261 
such as C. albicans or the prognosis of Candida BSIs (data not 262 
shown).  Although the BDG values that reflect the burden of 263 
Candida species and the half-life are still unknown, when higher 264 
BDG values are present, ocular candidiasis may have already 265 
occurred in these patients, even if they are asymptomatic. 266 
Despite the high prevalence of ocular candidiasis, periodic 267 
ophthalmologic examinations are rarely performed in patients 268 
susceptible to opportunistic infection.  According to the IDSA 269 
guidelines for invasive candidiasis, ophthalmologists should 270 
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investigate each patient for the presence of ocular candidiasis 271 
(Pappas et al., 2009), but the optimal timing for this evaluation 272 
has not been established.  Previous studies have advised an 273 
interval of < 14 days between the start of treatment and the first 274 
retinal abnormality, an interval that is consistent with candidal 275 
chorioretinitis (Rodrguez-Adria´n et al., 2003; Krishna et al., 276 
2000).  Although the optimal treatment for endogenous ocular 277 
candidiasis has not been clearly established yet, fluconazole and 278 
voriconazole appear to be the most effective (pappas et al., 2009; 279 
Khan et al., 2007).  In our study, 80% of cases were diagnosed 280 
within 7 days, and the antifungal agents were changed from 281 
micafungin to azoles or amphotericin in 16 of the 42 ocular 282 
candidiasis cases.  If fundoscopy was performed later, the 283 
opportunity for the earlier administration of potentially more 284 
optimal antifungal agents might have been missed.  In our study, 285 
more than 80% of the ocular candidiasis cases were chorioretinitis, 286 
which usually does not require surgical interventions.  Many 287 
patients completed the course of antifungal therapy without any 288 
visual disturbance.  We speculate that earlier diagnosis and 289 
treatment resulted in the improved prognosis regarding visual 290 
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acuity.  On the other hand, some ocular candidiasis cases were 291 
diagnosed by a second fundoscopic examination more than 8 days 292 
later.  Ideally, when we consider a strategy based on the fact that 293 
earlier diagnosis yields a better prognosis, fundoscopic 294 
examination should be performed within first 7 days of antifungal 295 
therapy, especially in those with C. albicans BSIs and higher BDG 296 
values.  In addition, follow-up fundoscopic examination should 297 
also be considered in severely immunosuppressed patients, even 298 
if the first fundoscopic examination yielded negative results. 299 
 300 
Study limitations 301 
This study has several limitations, including the fact that most of 302 
the patients without ocular candidiasis were not re-examined 303 
serially.  Conceivably, the disseminated fungal lesions could have 304 
arisen in healthy eyes after the initial exam and therefore may 305 
have been missed in some cases.  Second, approximately 7.2% of 306 
the Candida BSI patients did not consult ophthalmologists for 307 
their underlying conditions.  During discussion with those 308 
patients about the risk factors for ocular candidiasis, fundoscopy 309 
may have been indicated but not performed in some cases.  310 
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Thirdly, we included the possible cases of ocular candidiasis who 311 
had severe underlying diseases in this study.  The prevalence 312 
rate of ocular candidiasis might have been much lower than 313 
reported here. 314 
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Figure 1 Cumulative incidence of ocular candidiasis 402 
 403 
Ocular candidiasis was diagnosed within 7 days after positive 404 
blood culture in 43 patients, whereas 11 patients were diagnosed 405 


















  63.14 ± 19.8   0.923 
Male 28 51.9% 80 53.3% 0.875 
Malignancy 41 75.9% 60 40.0% <0.001 
Diabetes mellitus 12 28.6% 22 17.3% 0.210 
Digestive tract involvement 35 68.6% 61 41.5% 0.001 
Immunosuppressive agent 20 37.0% 32 21.3% 0.083 
Antibiotic within one month 46 86.8% 112 74.7% 0.083 
Surgery within one month 17 31.5% 46 30.7% 0.911 
C. parapsilosis 3 5.6% 35 23.3% 0.002 
C. albicans 40 74.1% 67 44.7% <0.001 
C. glabrata 5 9.3% 19 12.7% 0.626 
C. tropicalis 5 9.3% 18 12.0% 0.862 
High beta-D-glucan (N=88) 29 74.4% 31 34.4% <0.001 
Time to first negative blood 




5.32 ± 3.40, 
1-27 
  0.787 
Blood culture to antifungal 




2.34 ± 2.81, 
1-5 
  0.117 
First sign of infection to 




1.56 ± 2.17, 
1-11 
  0.920 
2 
 
mean, range (days) 
Sign of infection to 





2.36 ± 2.53, 
1-9 
  0.872 
Interval between positive 
fungal culture and catheter 




0.72 ± 1.82, 
1-3 
  0.647 
30-day mortality 14 25.9% 28 18.7% 0.326 
 2 
Table 2  Results of multilvariate regression analysis of factors 
associated with ocular candidiasis 
 
 P value Exp(B) 95% CI 
(1,3)-β-D-glucan high 0.001 9.99 2.60-21.3 
C. albicans 0.034 3.68 1.11-12.2 
Digestive tract involvement 0.290   
Malignancy 0.714   
Immunosuppressive agent 0.625   
Antibiotic within one month 0.483   
 
